SuperworthBluejay Diagnostics EPS BJDX
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$8.68
- Latest quarter, Q2 FY26
- −$1.12
- Fiscal year 2025
- −$24.71
Bluejay Diagnostics' earnings per share was −$8.68 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.12.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$24.71 | n/a |
| FY2024 | −$2922.36 | n/a |
| FY2023 | −$14694.00 | n/a |
| FY2022 | −$14752.00 | n/a |
| FY2021 | −$13120.00 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.12 | n/a | −$8.68 | |
| Q1 FY26 | −$1.95 | n/a | −$13.20 | |
| Q4 FY25 | −$1.57 | n/a | −$24.71 | |
| Q3 FY25 | −$4.04 | n/a | −$34.06 | |
| Q2 FY25 | −$5.64 | n/a | −$337.78 | |
| Q1 FY25 | −$13.46 | n/a | −$1356.78 | |
| Q4 FY24 | −$10.92 | n/a | −$2922.36 | |
| Q3 FY24 | −$307.76 | n/a | −$5887.44 | |
| Q2 FY24 | −$1024.64 | n/a | −$8913.68 | |
| Q1 FY24 | −$1579.04 | n/a | −$12289.04 | |
| Q4 FY23 | −$2976.00 | n/a | −$14694.00 | |
| Q3 FY23 | −$3334.00 | n/a | −$15494.00 |
Against its peers
Companies in Healthcare nearest Bluejay Diagnostics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BJDXBluejay Diagnostics | −$8.68 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bluejay Diagnostics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.